Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
4.220
+0.300 (7.65%)
At close: Mar 20, 2026, 4:00 PM EDT
4.260
+0.040 (0.95%)
After-hours: Mar 20, 2026, 4:10 PM EDT
IMDX Revenue
Insight Molecular Diagnostics had revenue of $260.00K in the quarter ending September 30, 2025, with 126.09% growth. This brings the company's revenue in the last twelve months to $4.40M, up 520.87% year-over-year. In the year 2024, Insight Molecular Diagnostics had annual revenue of $1.88M with 25.15% growth.
Revenue (ttm)
$4.40M
Revenue Growth
+520.87%
P/S Ratio
27.74
Revenue / Employee
$89,837
Employees
49
Market Cap
122.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.88M | 378.00K | 25.15% |
| Dec 31, 2023 | 1.50M | 545.00K | 56.89% |
| Dec 31, 2022 | 958.00K | -1.24M | -56.41% |
| Dec 31, 2021 | 2.20M | 982.00K | 80.76% |
| Dec 31, 2020 | 1.22M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 824.50M |
| Castle Biosciences | 344.23M |
| Fulgent Genetics | 322.67M |
| MDxHealth | 107.88M |
| FONAR | 106.03M |
| Prenetics Global | 92.39M |
| Biodesix | 88.50M |
| Burning Rock Biotech | 77.14M |
IMDX News
- 1 day ago - iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference - GlobeNewsWire
- 8 days ago - Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score - GlobeNewsWire
- 18 days ago - Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission - GlobeNewsWire
- 5 weeks ago - iMDx Announces $26.0 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring - GlobeNewsWire
- 2 months ago - iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation - GlobeNewsWire
- 2 months ago - iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch - GlobeNewsWire
- 2 months ago - iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - GlobeNewsWire